Evaluation of CLP in Heart Failure Patients With Chronic Kidney Disease

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effects of CLP on serum potassium and signs and symptoms of fluid overload in heart failure patients with chronic kidney disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sorbent Therapeutics
• Collaborator: Pharmaterra

Criteria

Inclusion Criteria:

• Heart failure with New York Heart Association (NYHA) Classification III or IV

• Hospitalization for heart failure decompensation associated with fluid overload within the last six months

• Chronic kidney disease

• Must be able to understand study procedures and willing and able to provide written informed consent

Exclusion Criteria:

• No hospitalization within 4 weeks of Baseline Visit

• In the investigator's judgment, any cardiovascular, renal, hepatic, endocrine, gastrointestinal, neurological or other disease or condition that makes the patients study participation unsafe

• History or presence of gastrointestinal conditions such as severe constipation or gastrointestinal tract strictures

• Current dialysis patient, or anticipated need for dialysis during study participation